Cesarean section
Conditions
Interventions
Experimental group:Transversus Abdominis Plane Block With Liposomal Bupivacaine
Control group:Bupivacaine combined with dexamethasone
Sponsors
Department of Anesthesiology, General Hospital of Xinjiang military region
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18 and above. two.. For term pregnancies ranging from 37 to 42 weeks, cesarean section is planned. 3.ASA grade ? or ?. 4. Be able to provide informed consent, comply with the schedule of study visits, and complete all research evaluations. 5. Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients whohave a high-risk pregnancy (eg, multiple gestations, pregnancy resulting from in vitro fertilization, gestational diabetes, prolonged bed rest required for medical reasons) 2. Patients with a pregnancy-induced medical condition or complication (eg, hypertension,pre-eclampsia, chorioamnionitis) 3. Patients with =3 prior cesarean deliveries 4. Prepregnancy body mass index >50 kg/m^2 or otherwise not anatomically appropriate to undergo a TAP block 5. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (eg, amide-type local anesthetics, opioids,bupivacaine, NSAIDs, spinal anesthesia) 6. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or tubal ligation 7. Severely impaired renal or hepatic function (eg, serum creatinine level >2 mg/dL [176.8µmol/L], blood urea nitrogen level >50 mg/dL [17.9 mmol/L], serum AST level >3 times the ULN or ALT level >3 times the ULN 8. Patients at an increased risk for bleeding or a coagulation disorder (defined as platelet count less than 80,000 × 10^3/mm^3 or international normalized ratio greater than 1.5) 9. Any psychiatric or other disease in the mother that would constitute a contraindication to participation in the study or cause the mother to be unable to comply with the study requirements 10. History of, suspected, or known addiction to or abuse of illicit drug(s), prescriptionmedicine(s), or alcohol within the past 2 years 11. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the patient’s participation in this study 12. Previous participation in a liposomal bupivacaine study 13. Any clinically significant event or condition uncovered during the surgery (eg, excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject’s postsurgical coursea 14. Received the epidural component of CSE anesthesia during participation in the studya
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score 24 hours after operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS score 48 hours after operation;VAS score 72 hours after operation;Opioid consumption 24 hours after operation;Opioid consumption 48 hours after operation;Opioid consumption 72 hours after operation; Postoperative rescue analgesia; Postoperative adverse reactions; | — |
Countries
China
Contacts
Public ContactYin Maojing
Department of Anesthesiology, General Hospital of Xinjiang military region
Outcome results
None listed